OHDSI
OBSERVATIONAL HEALTH DATA SCIENCES AND INFORMATICS

2015 Symposium Agenda

Time	Description
7:30 – 8:30am	Registration
8:00 – 8:30am	Introductions
8:30 – 10:00am	**Welcome to the journey: Overview of OHDSI : past, present, future** • **Speaker:** Patrick Ryan, PhD, Sr. Director and Head, Epidemiology Analytics, Janssen Research & Development • **Description:** Observational Health Data Sciences and Informatics (OHDSI, pronounced "Odyssey") is an international collaborative whose goal is to create and apply open-source data analytic solutions to a large network of health databases to improve human health and wellbeing. OHDSI's mission is to transform medical decision making by creating reliable scientific evidence about disease natural history, healthcare delivery, and the effects of medical interventions through large-scale analysis of observational health databases. We will provide an overview of OHDSI's focus to research, develop, and apply shared solutions for 3 key analytical use cases: clinical characterization, population-level estimation, and patient-level prediction. We will highlight the progress to date and provide a vision for how an open-science approach to evidence generation can accelerate observational research around the world.
10 – 10:15am	Break
10:15 – 11:15am	**OHDSI in action: Real-world evidence for clinical characterization** • **Speaker:** George Hripcsak MD, MS, Chair of the Department of Biomedical Informatics at Columbia University Medical Center • **Description:** The OHDSI collaboration created an international data network with hundreds of millions of patient records from countries on four continents. To characterize the diversity of populations and the variance in care, OHDSI studied treatment pathways for three common diseases. The time from envisioning the study to analyzing the results from the first seven sites was just three weeks. Heterogeneity among treatment pathways was studied, looking at country, type of practice, and type of record (health record versus claims data) as sources of variance. Trends in monotherapy were studied, as well as uniqueness of the pathways. Large-scale international observational research appears to be feasible.
11:15 – 12:15pm	**OHDSI in action: Open-source analytics for patient-centered evidence** • **Speaker:** Jon Duke, MD, Senior Scientist, Regenstrief Institute • **Description:** OHDSI's mission is to transform medical decision-making by creating

	reliable scientific evidence from observational health data. Implicit in this mission is the translation of the knowledge generated by the OHDSI community into tools that benefit and inform patients and providers directly. In this session, we will introduce one such tool recently developed by the community that connects traditional health information resources with data generated by the OHDSI network. Specifically, we will delve into the drug product labeling for several commonly prescribed medications and show how OHDSI can complement and illuminate the safety information found in these important documents.
12:15 – 2:45pm	**OHDSI collaborator showcase** • Poster session of OHDSI research • Software demonstrations of OHDSI open-source tools (See attached list of tools) • OHDSI 101 and ETL 101 stations *During this time, lunch will be provided*
2:45 – 3:45pm	**Panel Discussion – Experiences from the OHDSI international data network** **Description:** A common data model (CDM) allows for the systematic analysis of disparate observational databases. The concept behind this approach is to transform data contained within disparate databases into a common format (data model), and then perform systematic analyses using a library of standard analytic routines that have been written based on the common format. The OHDSI data network has adopted the Observational Medical Outcomes Partnership (OMOP) CDM which currently covers over 600 million patients within 11 countries around the world. During this panel session we will hear from OHDSI data holders from America, Europe, Asia and Africa. Each panelist will share their perspectives on: (1) Why they chose to participate in the network (2) The benefits and challenges of the data network (3) Shared strategies to make our collaboration stronger **Panelists:** • Christian Reich, MD, PhD, Vice President of Real World Evidence Systems, IMS Health • Rae Woong Park, MD, PhD, Professor, Ajou University School of Medicine, South Korea • Peter Rijnbeek, PhD Assistant Professor, Erasmus Medical Center • Parsa Mirhaji, MD, PhD, Director of Clinical Research Informatics at Montefiore Healthcare System, Albert Einstein College of Medicine • Paul Biondich, MD, Founder and President, OpenMRS
3:45 – 4:00pm	Break
4:00 – 5:30pm	**Panel Discussion – The Value and Challenges of Evidence from Observational Data: A Multi-Stakeholder Perspective** **Description:** To close out the day, we want to hear back from the broader healthcare community. The aim of this panel is to give each stakeholder group an opportunity to share their perspectives about the OHDSI program and how OHDSI tools could benefit their work. This discussion will focus on: (1) Multi-stakeholder perspectives on the current state of observational data use for generating evidence to support decision making (2) The most immediate / largest needs that require evidence from observational data (3) Reflections about the objectives of the OHDSI community and progress that has been made to date (4) Key drivers within each stakeholder group which will enable reliable evidence generation from observational data

	Panelists: • Moderator: David Madigan, PhD, Executive Vice President and Dean of the Faculty of Arts and Sciences at Columbia University • Invited: Robert Califf, MD, Deputy Commissioner of Medical Products and Tobacco, US Food and Drug Administration • Robert Ball, MD, MPH, ScM, Deputy Director – Office of Surveillance and Epidemiology, CDER, US Food and Drug Administration • Nareesa Mohammed-Rajput, MD, Medical Director of Clinical Informatics, Suburban Hospital part of Johns Hopkins Medicine • Maryan Zirkle MD, MS, MA, Program Officer – CER Methods and Infrastructure Program, PCORI • Lesley Wise, Vice President of PV Risk Management and Pharmacoepidemiology, Takeda Pharmaceuticals
5:30pm	Closing remarks